Evidence map›Paper›PMID 36440548›Full record

ArticleJournal of cellular and molecular medicine2022

Application of T-cell receptor repertoire as a novel monitor in dynamic tracking and assessment: A cohort-study based on RA patients.

Peiqing Yang, Yijing He, Pingying Qing, Wangdong Xu, Dan Xie, Jean-Baptiste Cazier, Xiao Liu, Csilla Varnai, Yi Zhou, Yi Zhao and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Peiqing YangDepartment of Rheumatology, West China Hospital, Sichuan University, Chengdu, China.
Yijing HePrecision Medicine Key Laboratory of Sichuan Province & Precision Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Pingying QingDepartment of Rheumatology, West China Hospital, Sichuan University, Chengdu, China.
Wangdong XuDepartment of Rheumatology, West China Hospital, Sichuan University, Chengdu, China.
Dan XiePrecision Medicine Key Laboratory of Sichuan Province & Precision Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Jean-Baptiste CazierCenter for Computational Biology, University of Birmingham, Birmingham, UK.
Xiao LiuBGI-Shenzhen and Shenzhen Key Laboratory of Transomics Biotechnologies, BGI-Shenzhen, Shenzhen, China.
Csilla VarnaiCenter for Computational Biology, University of Birmingham, Birmingham, UK.
Yi ZhouDepartment of Medical Affairs, West China Hospital, Sichuan University, Chengdu, China.
Yi ZhaoDepartment of Rheumatology, West China Hospital, Sichuan University, Chengdu, China.
Huairong TangHealth Management Center, West China Hospital of Sichuan University, Chengdu, China.
Xiaoming YinBGI Genomics, BGI-Shenzhen, Shenzhen, China.
Yi LiuDepartment of Rheumatology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-4811-0156
Sichuan University · CNBGI Group (China) · CNBirmingham City University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell receptor repertoire (TCRR) sequencing has been widely applied in many fields as a novel tool. This study explored characteristics of TCRR in detail with a cohort of 598 rheumatoid arthritis (RA) patients before and after anti-rheumatic treatments. We highlighted the abnormal TCRR distribution in RA characterized by decreased diversity and increased proportion of hyperexpanded clones (HECs), which was potentially attributed to skewed usage of global V/J segments but not a few certain ones. Enriched motifs analysis in RA community demonstrated the huge heterogeneity of CDR3 sequences, so that individual factors are strongly recommended to be taken into consideration when it comes to clinical application of TCRR. Disease-modifying antirheumatic drugs (DMARDs) can regulate immune system through recovery of TCRR richness to relieve symptoms. Remarkably, sensitive gene profile and advantageous gene profile were identified in this study as new biomarkers for different DMARDs regimens.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidClone CellsCohort StudiesHumansReceptors, Antigen, T-CellAntirheumatic AgentsReceptors, Antigen, T-CellbiomarkersDMARDsnext-generation sequencingrheumatoid arthritisT-cell receptor repertoire

Identifiers

PMID36440548
PMCPMC9753462
OpenAlexW4310214346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.